Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 1
2006 1
2008 1
2010 1
2011 3
2013 1
2014 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
KARYOTYPE: Very high-risk abnormalities include -7, inv (3), i(17q), +21, +19, 12p- and 11q-. Favorable risk abnormalities include normal karyotype or isolated +9, 13q-, 20q-, 1q abnormalities and loss of Y chromosome. ...Drug therapy in MF is currentl …
KARYOTYPE: Very high-risk abnormalities include -7, inv (3), i(17q), +21, +19, 12p- and 11q-. Favorable risk abnormalities include no …
Improved clinical utility of preimplantation genetic testing through the integration of ploidy and common pathogenic microdeletions analyses.
Caroselli S, Figliuzzi M, Picchetta L, Cogo F, Zambon P, Pergher I, Girardi L, Patassini C, Poli M, Bakalova D, Cimadomo D, Findikli N, Coban O, Serdarogullari M, Favero F, Bortolato S, Anastasi A, Capodanno F, Gallinelli A, Brancati F, Rienzi L, Ubaldi FM, Jimenez-Almazán J, Blesa-Jarque D, Miravet-Valenciano J, Rubio C, Simòn C, Capalbo A. Caroselli S, et al. Hum Reprod. 2023 Apr 3;38(4):762-775. doi: 10.1093/humrep/dead033. Hum Reprod. 2023. PMID: 36824049
STUDY QUESTION: Can chromosomal abnormalities beyond copy-number aneuploidies (i.e. ploidy level and microdeletions (MDs)) be detected using a preimplantation genetic testing (PGT) platform? ...WHAT IS KNOWN ALREADY: Standard methodologies employed in preimplantation genet …
STUDY QUESTION: Can chromosomal abnormalities beyond copy-number aneuploidies (i.e. ploidy level and microdeletions (MDs)) be detecte …
Genetic stratification of neuroblastoma for treatment tailoring.
Jeison M, Yaniv I, Ash S. Jeison M, et al. Future Oncol. 2011 Sep;7(9):1087-99. doi: 10.2217/fon.11.87. Future Oncol. 2011. PMID: 21919696 Review.
The clinical behavior is variable, ranging from spontaneous regression to fatal progression despite aggressive therapy. The most highly statistically significant and clinically relevant factors that are currently used for classification include stage, age, histopathologic …
The clinical behavior is variable, ranging from spontaneous regression to fatal progression despite aggressive therapy. The most high …
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, Rasmussen M, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Geisler C, Juliusson G, Rosenquist R. Gunnarsson R, et al. Haematologica. 2011 Aug;96(8):1161-9. doi: 10.3324/haematol.2010.039768. Epub 2011 May 5. Haematologica. 2011. PMID: 21546498 Free PMC article.
BACKGROUND: High-resolution genomic microarrays enable simultaneous detection of copy-number aberrations such as the known recurrent aberrations in chronic lymphocytic leukemia [del(11q), del(13q), del(17p) and trisomy 12], and copy-number neutral loss of heterozygo …
BACKGROUND: High-resolution genomic microarrays enable simultaneous detection of copy-number aberrations such as the known recurrent aberrat …
Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management.
Ribeiro IP, Marques F, Caramelo F, Pereira J, Patrício M, Prazeres H, Ferrão J, Julião MJ, Castelo-Branco M, de Melo JB, Baptista IP, Carreira IM. Ribeiro IP, et al. Cell Oncol (Dordr). 2014 Feb;37(1):29-39. doi: 10.1007/s13402-013-0161-5. Epub 2013 Dec 19. Cell Oncol (Dordr). 2014. PMID: 24353162
PURPOSE: The identification of genetic markers associated with oral cancer is considered essential to improve the diagnosis, prognosis, early tumor and relapse detection and, ultimately, to delineate individualized therapeutic approaches. Here, we aimed at identifying such …
PURPOSE: The identification of genetic markers associated with oral cancer is considered essential to improve the diagnosis, prognosis, earl …
Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion.
Ding W, Ferrajoli A. Ding W, et al. Hematology Am Soc Hematol Educ Program. 2010;2010:90-2. doi: 10.1182/asheducation-2010.1.90. Hematology Am Soc Hematol Educ Program. 2010. PMID: 21239776 Review.
A 55-year-old man presented with fever, night sweats, and weight loss of about 20 lbs. in the prior 6 months. Physical examination revealed multiple cervical, axillary, and inguinal lymphadenopathy. ...
A 55-year-old man presented with fever, night sweats, and weight loss of about 20 lbs. in the prior 6 months. Physical examination re …
Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility.
Leslie A, Stewart A, Baty DU, Mechan D, McGreavey L, Smith G, Wolf CR, Sales M, Pratt NR, Steele RJ, Carey FA. Leslie A, et al. Genes Chromosomes Cancer. 2006 Feb;45(2):126-35. doi: 10.1002/gcc.20271. Genes Chromosomes Cancer. 2006. PMID: 16235243

KRAS mutation correlated with 12p gain (P < 0.001) and TP53 mutation with both 20q gain and 18q loss (P = 0.03 for both). In addition, we have identified two chromosomal aberrations, gain of 13q and loss of 11q, that correlate with the presence of s

…

KRAS mutation correlated with 12p gain (P < 0.001) and TP53 mutation with both 20q gain and 18q loss (P = 0.03 for both). In addit

…
Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection.
Zhang L, Poh CF, Lam WL, Epstein JB, Cheng X, Zhang X, Priddy R, Lovas J, Le ND, Rosin MP. Zhang L, et al. Oral Oncol. 2001 Sep;37(6):505-12. doi: 10.1016/s1368-8375(00)00140-8. Oral Oncol. 2001. PMID: 11435177
In this study, we constructed a detailed clinical history of 66 mild and moderate dysplasias in order to determine how treatment affected outcome, and to evaluate the effect of treatment on lesions with different genetic profiles, which are defined by patterns of loss of h …
In this study, we constructed a detailed clinical history of 66 mild and moderate dysplasias in order to determine how treatment affected ou …
Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia.
Huh J, Jung CW, Kim JW, Kim HJ, Kim SH, Shin MG, Kim YK, Kim HJ, Suh JS, Moon JH, Sohn SK, Nam GH, Lee JE, Kim DH. Huh J, et al. Ann Hematol. 2011 Nov;90(11):1255-64. doi: 10.1007/s00277-011-1195-2. Epub 2011 Mar 8. Ann Hematol. 2011. PMID: 21384125
Thirty-nine clonal aberrations (CAs) were identified (35 losses, two gains, two copy neutral loss of heterozygosity) that were not detected by metaphase cytogenetics in 25 patients (21%). ...Copy number gains were identified at 8p and 9p, and losses at 2q, 7q, 8q, 9q, 1 …
Thirty-nine clonal aberrations (CAs) were identified (35 losses, two gains, two copy neutral loss of heterozygosity) that were not de …
Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia.
Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de Jong D, Eldering E, van Oers MH, Mellink CH, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS. Gunn SR, et al. J Mol Diagn. 2008 Sep;10(5):442-51. doi: 10.2353/jmoldx.2008.080033. Epub 2008 Aug 7. J Mol Diagn. 2008. PMID: 18687794 Free PMC article.
In the current study, commercially available bacterial artificial chromosome and oligonucleotide array CGH platforms were used to identify chromosomal alterations of prognostic significance in 174 CLL cases. ...Genomic changes involving loci currently interrogated b …
In the current study, commercially available bacterial artificial chromosome and oligonucleotide array CGH platforms were used to ide …
11 results